SCHEMBL7136555

SCHEMBL7136555

COC(=O)CC[C@@H]1C[C@@H](SCc2ccc(OC)cc2)CN1S(C)(=O)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.37
MMP13 P45452 3/20 0.36
MMP1 P03956 2/20 0.36
MMP3 P08254 2/20 0.36
MMP9 P14780 2/20 0.36
MMP2 P08253 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
HTRA1 Q92743 1/20 0.36
GAA P10253 1/20 0.36
TP53 P04637 1/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
MMP8 P22894 1/20 0.35
MMP12 P39900 1/20 0.35
MMP7 P09237 1/20 0.35
HTT P42858 1/20 0.34
KDM4E B2RXH2 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7136556 1.00 ALDH1A1 (0.37) ALDH1A1MMP13MMP1MMP3MMP9
SCHEMBL7140145 0.92 HTT (0.38) ALDH1A1MMP13MMP1MMP3MMP9
SCHEMBL7140147 0.92 HTT (0.38) ALDH1A1MMP13MMP1MMP3MMP9
SCHEMBL5410375 0.86 HTRA1 (0.34) ALDH1A1MMP13MMP1MMP3MMP9
SCHEMBL5410379 0.86 HTRA1 (0.34) ALDH1A1MMP13MMP1MMP3MMP9
SCHEMBL5405046 0.85 SIGMAR1 (0.38) ALDH1A1MMP13MMP1MMP3MMP9
SCHEMBL5405049 0.85 SIGMAR1 (0.38) ALDH1A1MMP13MMP1MMP3MMP9
SCHEMBL5409672 0.85 RAB9A (0.40) TP53
SCHEMBL5409681 0.85 RAB9A (0.40) TP53
SCHEMBL7151570 0.84 ALDH1A1 (0.47) ALDH1A1MMP13MMP1MMP3MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ALDH1A1 767/4885MMP13 96/4885MMP1 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.